Which evidence‑based psychotherapies are appropriate to refer a patient with substance use disorder?

Evidence-Based Psychotherapy Referral Options for Substance Use Disorder

You should refer patients with substance use disorder to Cognitive Behavioral Therapy (CBT), Contingency Management (CM), Motivational Enhancement Therapy (MET), or Community Reinforcement Approach (CRA)—all are evidence-based first-line psychotherapy options that perform equivalently when combined with appropriate pharmacotherapy. 1

Primary Psychotherapy Modalities

The following psychotherapies have robust evidence supporting their use:

Tier 1: Strongest Evidence Base

• Cognitive Behavioral Therapy (CBT): Time-limited, multisession intervention targeting cognitive, affective, and environmental risks for substance use. Provides behavioral self-control skills training for abstinence or harm reduction. Shows small-to-moderate effects that are most pronounced at early follow-up (1-6 months post-treatment). 1, 2

• Contingency Management (CM): Behavioral approach providing tangible rewards for drug-free urine samples. For stimulant use disorders (cocaine/amphetamines), CM combined with Community Reinforcement Approach is the single most effective intervention (OR 2.84 vs. usual care at end of treatment; OR 7.60 at 12 weeks). 3, 4

• Motivational Enhancement Therapy (MET): Effectively addresses inadequate motivation and enhances treatment engagement. Produces significant short-term outcomes and sustains motivation throughout treatment. 5

• Community Reinforcement Approach (CRA): Multi-layered intervention involving functional analysis, coping-skills training, and social/familial/recreational/vocational reinforcements. Shows superior long-term outcomes, particularly when combined with CM. 3

Tier 2: Supportive Evidence

• 12-Step Facilitation Programs: Set of guiding principles for self-help recovery. Can be offered but shows less robust evidence than the above modalities. 3

• Mindfulness-Based Interventions: Show benefits for specific outcomes (craving, emotion regulation, stress tolerance) but with heterogeneous effects. Requires careful screening and monitoring—may be contraindicated in high-complexity contexts or certain clinical profiles. 6, 7

Substance-Specific Considerations

Alcohol Use Disorder

• CBT and multicomponent approaches show most consistent support 6
• All first-line psychotherapies perform well when combined with FDA-approved pharmacotherapy (naltrexone, acamprosate, disulfiram) 1

Stimulant Use Disorders (Cocaine/Amphetamines)

• CM plus CRA is the gold standard (OR 2.44 vs. CBT alone; OR 3.31 vs. non-contingent rewards) 3
• This combination also reduces dropout rates significantly (OR 3.92 at 12 weeks vs. usual care) 3
• Contingency management represents the current standard of care for stimulant use disorders 4

Opioid Use Disorder

• Psychosocial interventions should be adjunctive and optional—never mandatory—when combined with medication-assisted treatment (methadone, buprenorphine) 8
• CBT, MET, and CRA all show efficacy 1

Cannabis and Other Substances

• CBT and motivational interventions are first-line 7
• CM shows particular effectiveness for engagement and short-term abstinence 6

Critical Implementation Points

Key Finding: CBT does not outperform other evidence-based therapies (MET, CM, CRA) when combined with pharmacotherapy. The critical distinction is between evidence-based psychotherapy versus usual care/nonspecific counseling. 1

What NOT to Refer For

• Usual care or nonspecific drug counseling alone: Significantly inferior to structured evidence-based psychotherapy (effect size difference g = 0.18-0.28) 1
• Withdrawal management as standalone intervention: Should be avoided; must be part of comprehensive treatment 8
• Mandatory psychosocial interventions for opioid use disorder: Can be offered but should never be required as condition for receiving medication-assisted treatment 8

Delivery Format Options

• Face-to-face: Traditional gold standard
• Technology-assisted/digital interventions: Promising for expanding access and treatment continuity, though effectiveness depends heavily on adherence and clinical integration 6
• Group therapy: Shows small but significant effects on abstinence compared to no treatment, individual therapy, and other treatments. Moderately sized effects on mental health outcomes. 9

Practical Algorithm

1. Assess primary substance: Stimulants → prioritize CM + CRA; Alcohol → CBT or multicomponent; Opioids → any evidence-based therapy as adjunct to medication
2. Combine with pharmacotherapy when available: The combination consistently outperforms psychotherapy or pharmacotherapy alone 1
3. Choose any evidence-based modality (CBT, CM, MET, CRA): They perform equivalently—select based on availability and patient preference 1
4. Avoid usual care/nonspecific counseling: These show significantly inferior outcomes 1

Common Pitfalls

• Assuming CBT is superior to other evidence-based therapies: It is not—all evidence-based modalities perform similarly 1
• Requiring psychosocial treatment before prescribing medication for opioid use disorder: This creates barriers to life-saving treatment 8
• Using withdrawal management alone: Must be integrated into comprehensive treatment plan 8
• Applying mindfulness-based interventions universally: Requires screening; may be contraindicated in certain populations 6